Table 4. Examples of nanocarrier-based delivery for combining monoclonal antibody and anticancer drugs.
| Nanoparticles | Antibody & Chemo- Drugs |
Tumor Model | Results | Reference |
|---|---|---|---|---|
| Nanocapsules |
anti-HER2 antibody & DOX & paclitaxel |
Subcutaneous SKBR human breast adenocarcinoma |
pH responsive and HER2 targeting nanoparticles co- encapsulating dual anticancer drugs; enhanced efficacy against human breast cancer |
[117] |
| C225-ILS-DOX (liposome) |
anti-EGFR (HER1) & DOX |
Phase I & II: various tumor overexpressing EGFRs |
Phase I: well tolerated and safe and promising clinical activity for warranting phase II clinical trial |
[122, 123] |
| MM-302 (liposome) |
anti-HER2 scFv & DOX | Subcutaneous BT- 474 M3C5 human breast tumor |
Phase I: safe and signs of clinical activity in metastasized breast cancer patients; Increased bioavailability of DOX in tumor and nucleus compared to non-targeted liposome; Superior antitumor activity and 6- fold greater intracellular uptake in cancer cells |
[121, 124, 128] |